<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>It has been reported that K-ATP channel openers have a cardioprotective effect in <z:hpo ids='HP_0011009'>acute</z:hpo> <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> as a pharmacological preconditioning effect </plain></SENT>
<SENT sid="1" pm="."><plain>In the present study, the <z:hpo ids='HP_0011010'>chronic</z:hpo> effects of clinical K-ATP channel openers, ie, nicorandil (Nic) and mexiletine (Mex), on cardiac function were evaluated in a rat model of experimental autoimmune <z:mp ids='MP_0001856'>myocarditis</z:mp> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">EAM</z:e>) </plain></SENT>
<SENT sid="2" pm="."><plain>Nicorandil (3 or 10 mg/kg/day) or Mex (10 or 25 mg/kg/day) was administered to the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">EAM</z:e> rats, and the effects were compared with those in untreated <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">EAM</z:e> rats (control <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">EAM</z:e>) and sham rats without <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">EAM</z:e> on day 21 (<z:hpo ids='HP_0011009'>acute</z:hpo> phase) or day 60 (<z:hpo ids='HP_0011010'>chronic</z:hpo> phase) </plain></SENT>
<SENT sid="3" pm="."><plain>In the <z:hpo ids='HP_0011009'>acute</z:hpo> phase, the control <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">EAM</z:e> rats exhibited a reduced left ventricular ejection fraction (LVEF) and prolonged monophasic action potential duration (MAPD) </plain></SENT>
<SENT sid="4" pm="."><plain>Neither drug had an affect on the LVEF or degree of <z:mp ids='MP_0001856'>myocarditis</z:mp>, but Mex 25 mg suppressed the MAPD prolongation </plain></SENT>
<SENT sid="5" pm="."><plain>In the <z:hpo ids='HP_0011010'>chronic</z:hpo> phase, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">EAM</z:e>+Nic and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">EAM</z:e>+Mex 25 mg exhibited a higher LVEF than the control <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">EAM</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>Although the control <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">EAM</z:e> exhibited sustained MAPD prolongation, the other groups showed recovery of the MAPD in the <z:hpo ids='HP_0011010'>chronic</z:hpo> phase </plain></SENT>
<SENT sid="7" pm="."><plain>The mitochondorial redox state was lower in the control <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">EAM</z:e> than in the sham, and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">EAM</z:e>+Nic exhibited a similar level of the redox state as the sham in the <z:hpo ids='HP_0011010'>chronic</z:hpo> phase </plain></SENT>
<SENT sid="8" pm="."><plain>Nicorandil exhibited a cardioprotective effect through the protection of <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> function </plain></SENT>
<SENT sid="9" pm="."><plain>Mexiletine exhibited a cardioprotective effect possibly through a reduction in the calcium overload by shortening the MAPD in the <z:hpo ids='HP_0011009'>acute</z:hpo> phase </plain></SENT>
</text></document>